Zdrowie i gospodarka · 04/05/1999
FDA Announces Public Meeting to Discuss Approach to Assessing Preclinical Reproductive Toxicity Data
The FDA is hosting a public meeting to discuss its approach to evaluating preclinical data on reproductive toxicity in pharmaceuticals, with the goal of informing guidance on pharmaceutical reproductive risk.